Sabba Stephen L's Form 4 filing
Ligand Pharmaceuticals IncLGND · filed Mar 25, 2026
- Accession no.
- 0001104659-26-034308
- Filed
- Mar 25, 2026
- Trade date
- Mar 23, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $207.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sabba Stephen LCIK 0001442372 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | Common Stock | SSaleDisposed | −1,000 | $207.87F2 | −$207,870 | 32,793 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price, as represented in Column 4, represents an average price per share of the following transactions on 23 March 2026: 100 shares at $208.055000, 17 shares at $207.980000, and 883 shares at $207.850000.
Referenced by the price of 1 transaction in Table I.